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Introduction: A number of international guidelines have been developed to support primary care clinicians
improve the quality of care for patients with chronic heart failure at the end of life. The objective of this
study was to undertake a systematic evaluation of such guidelines in relation to end-of-life care.
Methods: A systematic literature search of research databases and guideline clearing houses was undertaken.
The selected guidelines were independently assessed by two researchers using the AGREE II quality criteria. A
data-extraction framework was devised based on the holistic needs assessment tool of the Gold Standards
Framework. The content of each guideline was then analysed using an approach similar to that used for the-
matic analysis.
Results: A total of 19 guidelines were included. Those guidelines with lower overall AGREE II scores covered
fewer domains on the holistic needs assessment. Across all guidelines the lowest scoring domain was appli-
cability and stakeholder involvement. Qualitative assessment showed that some guidelines adopt an
unwavering disease orientated approach to assessing patient need. Guidance around continuity of care, out
of hours care and after care was particularly poor in several guidelines. There was considerable heterogeneity
in the evidence presented even amongst those guidelines that achieved high AGREE II scores.
Conclusion: Combined quantitative and qualitative assessment demonstrates the importance of rigorous
guideline development. Whilst the variation in evidence presented could be a result of methodological het-
erogeneity in the development of guidelines, it raises important questions about the processes by which
evidence, information and knowledge become transformed into clinical guidelines.© 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Improving care for patients with heart failure at the end-of-life is a
national priority [1]. The overall long term survival rate is worse in
patients with heart failure than for men with colorectal cancer or
women with breast cancer [2]. Yet despite this, studies suggest that
patients with heart failure are less likely to receive high quality
end-of-life care compared to those who have a cancer diagnosis [3].
Over recent decades, a number of national and international organisa-
tions have developed heart failure guidelines to support clinicians in
primary care improve the quality of care of patients with advanced
heart failure. However, there has been no systematic evaluation of
such guidelines to date in relation to end-of-life care.
One of the key criticisms of care for people with advanced pro-
gressive illness is that care has been based on medical diagnosise reliability and freedom from
ation.
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er CC BY-NC-ND license.rather than need [3]. This is a problem as it results in care that is
both inequitable and not patient centred. The prior assessment of pa-
tient need has been identiﬁed as a marker of quality in the UK
End-of-Life Care Strategy, in order to ensure patients receive care
that is proactive and designed to meet patient need [4]. The “holistic
patient assessment” tool within the Gold Standard Framework (GSF)
toolkit suggests those domains which should be explored in order to
deliver high quality care [5]. It follows that a key question is “do cur-
rent guidelines support this approach, and if so how?”.
Given that themajority of care for those with chronic heart failure is
co-ordinated and delivered in primary care it is important that the
guidelines acknowledge role. Critiques of guidelines from a primary
care perspective include how they ignore the conceptual basis of caring
for those with advanced chronic disease in primary care [6]. For exam-
ple, the limitations of single disease models in those with co-morbid
disease and/or complex needs. Historically, guidelines have been built
on research that has not been gathered in primary care populations,
with the result that evidence is oftenweakwhen applied in this context.
Indeed,many patients are frustrated by practitioners' rigid use of guide-
lines formany conditions, andwant care that is individually tailored [7].
The purpose of this study is to assess national guidelines using two
complementary approaches, in order to identify whether guidelines
Fig. 1. Selection and appraisal of relevant guidelines.
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the management of heart failure are reviewed using 1) a standard
well validated generic guideline based assessment tool which pro-
vides quantitative ratings and 2) a qualitative thematic analysis to en-
rich the numerical assessment and enable comparison of the content
of the guidelines. The review forms a part of a programme of research
exploring patient needs in heart failure at the end-of-life.2. Method
MEDLINE, Web of Science (ISI), EMBASE, and the Cochrane library were searched
for recent (1996–2011) national guidelines using keywords such as “heart failure”
“primary care” and “guidelines” (full search strategy available on request). Inclusion
criteria were then applied to select the guidelines to be used in the review. Guidelines
had to be national or international. Those guidelines that were not available in the
English language were translated by a professional translator. The search was
supplemented with a web search of gridline clearing houses and relevant national
and international guideline producing organisations. Assessment was made on the
published guidelines given that these are what primary care clinicians would read.
Each guideline was assessed independently using the following approach (Fig. 1):Table 1
The relative ranking of the selected guidelines according to the six AGREE II domains.
Country guideline Scope and purpose Stakeholder involvement Rigour of
England and Wales [12] 89 89 96
Scotland [11] 72 78 92
Australia [23] 72 83 56
Europe [26] 81 52 84
Netherlands [10] 78 89 67
US (AHA) [15] 78 50 94
New Zealand [19] 89 72 75
US (HSFA) [27] 78 39 90
Canada [14] 67 67 58
Germany [28] 67 61 79
Brazil [18] 44 58 57
Northern Ireland [24] 56 44 90
Sweden [17] 56 56 58
Italy [13] 61 61 40
Denmark [22] 50 44 40
Japan [16] 61 39 48
Singapore [25] 56 39 40
Russia [21] 44 33 31
China [29] 39 28 35
% mean score of the two reviewers calculated according to the AGREE II scoring system. Ma2.1. Quantitative assessment
The selected guidelines were independently assessed using the latest version of the
Appraisal of Guidelines for Research and Evaluation tool (AGREE II) [8]. AGREE II consists
of 23 key items in six domains. These include: scope and purpose: concerned with overall
aim, speciﬁc clinical questions, and the target patient population (items 1–3); stakeholder
involvement: focuses on the extent of representation of the views of its intended users
(items 4–7); rigour of development: related to the process of synthesising evidence and
methods (items 8–14); clarity of presentation: deals with language and formatting
(items 15–17); applicability: pertaining to the organisational, behavioural, and cost impli-
cations (items 18–21); and editorial independence: concerned with the independence of
the recommendations and conﬂict of interest (items 22–23).
For each domain, questions are scored on a 4-point scale from 4 (strongly agree)
to 1 (strongly disagree) and then an overall percentage score is derived for each do-
main by summing all the scores of individual items and standardising the total as a
percentage of the maximum possible score for that domain. This approach is similar
to quality-assessment scoring systems used for assessing the quality of research pa-
pers in systematic reviews.
2.2. Qualitative analysis
The approach taken for qualitative analysis was adapted from that described by
Hegarty et al. [9]. A data-extraction frameworkwasdevised based on theholistic needs as-
sessment tool of the Gold Standards Framework. The holistic needs assessment deﬁnes
key areas of patient need at the end-of-life as relevant to primary care — physical, emo-
tional, personal, information and communication, control, out of hours, late (terminal)
care and aftercare. The text of each guideline was then analysed using an approach
based on thematic analysis of qualitative research data [9]. This was then applied to the
guidelines and reviewed independently using this coding and assessment process. The
coding process involved identifying where in a guideline a particular theme occurred,
then summarising the text into a data extraction template. Assessment involved judging
whether the theme was covered or not, and for some themes making a judgement
about the completeness of the guidance itself. The qualitative assessment did not examine
the strength of the evidence as this was assessed in detail using the AGREE II criteria.
3. Results
A total of twenty one chronic heart failure guidelines were identi-
ﬁed. Two guidelines identiﬁed by the search process were excluded be-
cause they were either for a speciﬁc population or had been withdrawn
from use. Nineteen national/international guidelines were included
[10–28]. All guidelines had been published within the last eight years.
Nine Guidelines were published in English— the remainder in their na-
tive language. Guideline length varied from 8 pages (Singapore) to 164
pages (Netherlands) resulting in considerable disparity in the amount
of information presented. There were some cross-referencing between
the guidelines selected — particularly amongst those guidelines that
had adopted European Society of Cardiology (ESC) or National Institute
of Clinical Excellence (NICE) guidelines as a framework. Rankings using
the AGREE II assessment tool are shown in Table 1. England andWales'development Clarity and presentation Applicability Editorial independence
100 92 92
94 79 92
89 79 75
83 68 86
78 75 67
89 46 92
100 63 50
94 42 92
100 50 92
89 58 67
83 67 100
83 67 50
72 58 67
61 33 58
61 33 58
61 38 33
81 38 17
50 42 25
33 21 33
ximum AGREE II score 100%.
Table 2
Qualitative appraisal of guidelines according to the Gold Standards Framework holistic needs assessment.
Physical Emotional Personal Social Information Control Out of hours Late care After care
England and
Wales [12]
Symptom control
complementary
therapy
Compliance
Depression
fears
relationships
understanding
expectations
Inner journey
patient/carer agenda
quality of life
Beneﬁts
care for carers
practical support
Within PHCT
between professionals
to and from patient/carer
Choice
treatment options
Continuity Patient aware
comfort measures
terminal care
non urgent treatment
stopped
Support team
Scotland [11] Symptom control
compliance
prn
medication
Depression
understanding
expectations
Patient/carer agenda
quality of life
Practical support Within PHCT
between professionals
to and from patient/carer
Advanced directives
choice
Continuity
communication
to OOH
medical support
Patient aware
Terminal care
rattle/agitation
non urgent treatment
stopped
Assessment/
audit
Australia [17] Symptom control
complementary
therapy
compliance
PRN medication
Depression
fears
relationships
understanding
expectations
Patient/carer agenda
quality of life
Care for carers Within PHCT
between professionals
to and from patient/carer
Advanced directives
choice
treatment options
Continuity
medical support
Patient aware
rattle/agitation
non urgent treatment
stopped
drugs/equipment
–
Europe (ESC) [26] Symptom control
compliance
PRN medication
Depression
fears
relationships
understanding
expectations
Inner journey
spiritual needs
quality of life
Practical support
care for carers
Within PHCT
between professionals
to and from patient/carer
Advanced directives
choice
place of death
treatment options
Continuity
medical support
Patient aware
terminal care
comfort measures
non urgent treatment
stopped
Family
support
support team
Netherlands [10] Symptom control
compliance
PRN medication
Depression
fears
understanding
expectations
Patient/carer agenda
quality of life
spiritual needs
Care for carers
practical support
Within PHCT
between professionals
to and from patient/carer
Advanced directives
choice
place of death
treatment options
Continuity
medical support
Patient aware
terminal care
drugs/equipment
non urgent treatment
stopped
Family
support
support team
US (AHA) [15] Symptom control
compliance
PRN medication
Understanding
expectations
Inner journey
patient/carer agenda
quality of life
– Within PHCT
between professionals
to and from patient/care
Advanced directives
treatment options
Continuity
medical support
Patient aware
terminal care
non urgent treatment
stopped
Assessment/
audit
New Zealand [19] Symptom control
PRN medication
Depression
fears
understanding
expectations
Inner journey
patient/carer agenda
quality of life
Beneﬁts
care for carers
practical support
Within PHCT
between professionals
to and from patient/carer
Advanced directives
choice
place of death
treatment options
Communication
to OOH
medical support
Patient aware
terminal care
rattle/agitation
non urgent treatment
stopped
Family
support
bereavement
follow-up
support team
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US (HSFA) [27] Symptom control
compliance
PRN medication
Understanding
expectations
Patient/carer agenda
quality of life
Practical support Between professionals
to and from patient/carer
Advanced directives
choice
place of death
treatment options
Continuity
communication
to OOH
medical support
Patient aware
drugs/equipment
terminal care
non urgent treatment
stopped
Family
support
Canada [14] Symptom control
compliance
prn medication
Depression
fears
relationships
understanding
expectations
Inner journey
patient/carer agenda
quality of life
Beneﬁts
care for carers
practical support
To and from patient/carer Advanced directives
choice
place of death
treatment options
Continuity
communication
to OOH
medical support
Terminal care
rattle/agitation
Family
support
support team
Germany [28] Symptom control
compliance
– – – – – – – –
Brazil [18] Symptom control
complementary
therapy
compliance
Depression
relationships
Inner journey
quality of life
– – – – – –
Northern Ireland [24] Symptom control
compliance
Depression
understanding
expectations
Patient/carer agenda
quality of life
spiritual needs
Beneﬁts
practical support
care for carers
Within PHCT
between professionals
to and from patient/carer
– Medical support Terminal care
non urgent treatment
stopped
Assessment/
audit
Sweden [17] Symptom control Understanding
expectations
– – – Between professionals – Terminal care
drugs/equipment
non urgent treatment
stopped
Assessment/
audit
Italy [13] Symptom control Understanding
expectations
inner journey
patient/carer agenda
quality of life
Practical support To and from patient/carer – – – –
Denmark [22] Symptom control – – – – – – – –
Japan [16] Symptom control
compliance
Depression Quality of life Beneﬁts
care for carers
To and from patient – – Comfort measures Family
support
support team
Singapore [25] Symptom control – Patient/carer agenda Beneﬁts – – – Rattle/agitation
drugs/equipment
Assessment/
audit
Russia [21] Symptom control Depression Quality of life – – – – – –
China [29] Symptom control
compliance
– – – – Choice – Terminal care –
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Scotland (SIGN), Australia, Europe (ESC) and the Netherlands. Ten
guidelines failed to score over 50% in all six domains — Brazil, China,
Denmark, Italy, Japan, Northern Ireland, Russia, and Singapore. Across
all guidelines the lowest scoring domains were applicability and stake-
holder involvement.
Thematic analysis of each guideline against using the holistic needs
assessment extraction framework is shown in Table 2. No guideline
demonstrated complete coverage of all domains. Results speciﬁc to
each domain include:
3.1. Physical needs
Most guidelines recommended the need for physical assessment at
the end-of-life, formany this was in the context of seeking specialist cli-
nician/palliative care input for intractable symptoms. Most guidelines
covered themanagement of speciﬁc symptoms e.g. dyspnoea. However,
the more general complaint of “fatigue” was poorly covered. Only
England, Wales, the Netherlands and ESC recommended the use of
validated tools or guidelines for symptommanagement. For medica-
tion reviews the emphasis in many guidelines was on compliance
rather than stopping non-essential medications at the end-of-life.
Only two guidelines made recommendations relating to adverse ef-
fects of medications and how this should be managed.
3.2. Emotional needs
Most guidelines focus on the identiﬁcation and pharmacological
treatment of depression. Only three guidelines discussed the use of
non-pharmacological interventions for treating depression in chronic
heart failure. Those guidelines that covered the patient's own under-
standing of expectations generally focus on issues of resuscitation,
switching off implantable deﬁbrillators and communicating prognosis.
Only the Netherlands' guideline explicitly discussed the importance of
exploring patients' fears.
3.3. Personal needs
Only ﬁve guidelines covered the importance of addressing spiritual
and religious needs. In contrast, twelve covered the importance of ex-
ploring the patient's inner journey. Those guidelines that focused on
quality of life generally highlighted that heart failure is associated
with a poor quality of life. Only one guideline explicitly stated that im-
proving quality of life should be the primary concern at the end-of-life.
3.4. Information and communication
Much emphasis was placed on the need for communication be-
tween clinician, patient and carer. However, few guidelines discussed
what the content of such communication should be. Only three guide-
lines indicated that this information should be individualised and antic-
ipatory. A small number of guidelines highlighted the need to be aware
of cultural issues in relation to communication.
3.5. Control and autonomy
Those guidelines that discussed “choice” generally did so in rela-
tion to supporting patient-centred care. One guideline discussed
choice in relation to drug treatment preferences. Several guidelines
discussed the use of advanced directives, living wills or advanced
care plans. Only a small number of guidelines outlined what contin-
gencies these documents should include in relation to heart failure
e.g. cardiac arrest. Only four guidelines explicitly discussed place of
death. Each highlighted that palliative care should be available
where the patient is. Only one highlighted that many patients are
not aware that palliative care can be delivered at home.3.6. Out of hours
The domain of “out of hours” was particularly poorly covered by
all guidelines. Whilst some emphasis was placed on support for
carers there was little discussion in relation to the delivery of medi-
cal care. Speciﬁc issues around co-ordination of care, place of death,
drugs and equipment, and resuscitation orders in the community
were not covered.
3.7. Late (terminal) care
Not all guidelines addressed late care. Those that did emphasised
that heart failure has an unpredictable disease trajectory. In relation to
stopping non-urgent treatment some guidelines emphasise that deci-
sions to stop routine medication, such as ACE inhibitors should be
made on the basis of intolerance, rather than be the aim of treatment it-
self. Others guidelines stated that any medication that detracts from a
peaceful death should be stopped. In addition, a number of guidelines
also outline the importance of deactivating pacemakers and implant-
able cardiac deﬁbrillators in the terminal phase.
3.8. Aftercare
Only one guideline explicitly discussed bereavement support for
family members and caregivers. Six guidelines covered the importance
of family support, emphasising the importance of psychosocial support.
No guideline explicitly discussed support teams e.g. bereavement sup-
port services, and contacts for the timely removal of equipment. Five
guidelines covered the importance of audit and assessment. This was
invariably set in the context of identifying quality indicators.
4. Discussion
The combined quantitative and qualitative assessment of national/
international chronic heart failure guidelines demonstrates consider-
able heterogeneity in the evidence presented in relation to needs at
the end-of-life. This variation was seen even amongst those guidelines
that achieved a high score on the AGREE II criteria. Given that all guide-
lines had access to a similar (if not the same) evidence base, this was
surprising. Whilst this could simply be a result of methodological het-
erogeneity in the development of guidelines, it raises important ques-
tions about the social and organisational processes by which evidence,
information and knowledge become transformed into clinical guide-
lines. For example, health care system structure, patient expectations
and the balance of power within those stakeholders involved. This is
particularly an important point given the considerable challenges
faced when undertaking research at the end-of-life.
Across all guidelines the lowest scoring domains were those of ap-
plicability and stakeholder involvement. These domains relate whether
i) existing barriers and facilitators that impact on the application of a
guideline have been considered and ii) whether the relevant profes-
sions had been involved in the guideline development, whether the
view and preferences of the target population had been sought and
whether the target users of the guideline are clearly deﬁned. Issues sur-
rounding applicability and stakeholder involvement are not conﬁned to
heart failure guidelines and have been highlighted by others [9]. It was
interesting to note that those guidelines that did score highly for stake-
holder involvement adopted a more patient-centred approach. For ex-
ample the guidelines from the Netherlands emphasise that “starting
point for optimal care is that which is person centred”.
The qualitative assessment showed that many guidelines adopt a
largely disease-orientated approach to assessing the needs of patients
with heart failure at the end of their lives. Similarly, many guidelines of-
fered little support for a ‘biographical’ or person-centred approach
which may be due to a paucity of evidence. Alternatively, selecting
studies only by their place in a hierarchy of designs could have a
2309G. Irving et al. / International Journal of Cardiology 168 (2013) 2304–2309similar effect. International guidelines, such as those developed by the
ESC, reﬂected important differences in end-of-life care legislation be-
tween countries. They exercised caution when presenting guidance on
subjects that are not consensual amongst all countries. For example, eu-
thanasia is illegal in many but not all countries.
5. Study limitations
The two authors that proposed the AGREE II score both were from
the UK and consequently some bias may be present. Potential limita-
tions of the AGREE II tool have previously been published [8]. Limita-
tions relating to the GSF tool itself include that the instrument
examines quality management at a practise level rather than at the
level of the individual doctors, at which most guidelines are aimed.
The review did not include other related policy developments, for ex-
ample, the World Health Organization guidance on palliative care
[30].
6. Implications for clinical practise and future research
Guidelines attempt to synthesise a substantial body of knowledge
into a coherent and manageable set of recommendations to support
clinical decision making. The complexity of addressing needs at the
end-of-life in heart failure means that short guidelines are always
likely to remain limited in their relevance and applicability to primary
care, whilst longer ones many not be read by busy clinicians— clearly
a balance is required. New initiatives such as “NICE pathways” may
present an opportunity to address this concern. With this in mind,
the ideal heart failure pathway would also recognise that:
• Adopting a person-centred approach to guideline development is
key to ensure that all bio-psycho-social needs are addressed.
• Guidance around continuity of care needs to be strengthened —
current guidance around out of hours care and after care is particu-
larly poor.
• Greater consideration is required on how to combine evidence from
primary palliative care given its inherent methodological complexity.
Finally, in terms of future primary care research, there remains a dis-
tinct lack of longitudinal evidence exploring patient self-perception of
complex needs. Amore critical approach to future studies looking at in-
dividual experiences of heart failure patients is required, in order to
identify where and when existing health care approaches are, and are
not, applicable. A comprehensive understanding of complex needs
over timewould facilitate and determine the appropriateness of current
health policy proposals for end-of-life care.
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